Hx009, a novel bsab dual targeting pd1 x cd47, demonstrates potent anti-lymphoma activity in preclinical models

HIGHLIGHTS

• who: Hang Ke from the IncUniversity of have published the research: HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models, in the Journal: Scientific Reports Scientific Reports
• how: Following the confirmation of the designed properties of HX009 in_vitro the authors evaluated the anti-lymphoma activity in_vivo using various preclinical models with certain predictive power 31. To explore the potential anti-lymphoma effects of HX009 the authors conducted several sets of in_vivo murine studies using multiple types of preclinical lymphoma models to answer specific questions | Vol.(1234567890) 135419 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.